🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

Investor Elliott wants GSK leadership settled before split

Published 07/01/2021, 03:59 AM
Updated 07/01/2021, 07:40 AM
© Reuters. FILE PHOTO: Company logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility, Britain October 26, 2020. REUTERS/Matthew Childs/File Photo
PFE
-
GSK
-

By Keith Weir

LONDON (Reuters) -Activist investor Elliott said GlaxoSmithKline (NYSE:GSK) should review its leadership and consider a sale of its consumer healthcare business as it confirmed on Thursday that it had taken a significant stake in the British pharmaceuticals group.

GSK last week set out plans for a separate listing next year of the consumer health business, which includes brands such as Sensodyne toothpaste and Advil painkillers, in the biggest shake-up for the company in two decades.

In a strongly worded letter to the GSK board, setting out five recommendations to tackle what it called years of underperformance, Elliott raised the pressure on Chief Executive Emma Walmsley while endorsing the planned split.

The hedge fund said GSK should add pharmaceutical and scientific expertise to its board and then decide who should run the two businesses, looking at internal and external candidates.

"Elliott strongly believes that the future CEOs of New GSK and CH must have the skillsets and expertise to match their respective tasks at hand," adding that existing management should remain in place for now.

Elliott's response had been awaited after reports in April that it had taken a multi-billion pound stake.

"Despite possessing strong businesses in attractive markets, GSK has failed to capture business opportunities due to years of under-management," Elliott said.

SEPARATION PLANNED

In its initial response, GSK said Elliott was raising "legacy issues".

GSK's "ambitious" plan was set out to realise significant value over the next decade, a spokesperson for the British company said.

"We believe our shareholders are supportive of this strategy, and that they are focused on GSK executing on it without distraction or delay. This is our clear priority," they added, saying a more detailed response would follow.

The split will allow GSK to focus on its core drugs and vaccines business, which has been hit by a lack of fast-growing products and patients deferring treatments due to the COVID-19 pandemic, weighing on its shares.

Walmsley, who has led GSK since 2017, said last week that GSK shares had underperformed for a long period and that she planned to stay on to lead the pharma and vaccines business.

The shares were up around 0.7% on Thursday.

"Our analysis suggests that GSK has an opportunity to generate up to 45% upside in its share price in the lead-up to its full separation, and much more in the years beyond," Elliott said.

© Reuters. FILE PHOTO: Company logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility, Britain October 26, 2020. REUTERS/Matthew Childs/File Photo

It also urged GSK to look at a full sale of the consumer health business, a joint venture with Pfizer (NYSE:PFE), should the opportunity arise and grant the vaccines business more autonomy within new GSK.

"Providing vaccines more autonomy could increase its talent retention and nimbleness ... maintaining separate divisional reporting for vaccines will allow investors to appropriately value GSK's crown jewel vaccines business," Elliott said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.